Tenaya Therapeutics Inc (TNYA)

NASDAQ
Currency in USD
0.455
-0.003(-0.65%)
Closed·
After Hours
0.469+0.014(+3.077%)
·
TNYA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 14 days
Fair Value
Day's Range
0.4420.467
52 wk Range
0.3944.960
Key Statistics
Edit
Prev. Close
0.458
Open
0.456
Day's Range
0.442-0.467
52 wk Range
0.394-4.96
Volume
1.12M
Average Volume (3m)
3.35M
1-Year Change
-89.73%
Book Value / Share
1.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TNYA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.429
Upside
+2,631.55%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

Tenaya Therapeutics Inc Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics Inc SWOT Analysis


Pivotal Gene Therapy
Tenaya Therapeutics approaches critical milestones in cardiac gene therapy development, with key clinical trial data expected in late 2024
AAV9 Vector Promise
Explore Tenaya's innovative use of AAV9 delivery vector, showing superior performance across species and potential for enhanced efficacy in humans
Market Positioning
Delve into Tenaya's strategic focus on MYBPC3-related hypertrophic cardiomyopathy, addressing a significant unmet need in cardiac genetic disorders
Financial Outlook
Analyst price target of $40 highlights potential upside, with stock performance closely tied to upcoming clinical trial outcomes and cash management
Read full SWOT analysis

Compare TNYA to Peers and Sector

Metrics to compare
TNYA
Peers
Sector
Relationship
P/E Ratio
−0.7x−4.0x−0.5x
PEG Ratio
−0.030.000.00
Price/Book
0.8x2.1x2.6x
Price / LTM Sales
-37.0x2.9x
Upside (Analyst Target)
-198.6%64.0%
Fair Value Upside
Unlock3.6%9.4%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.429
(+2,631.55% Upside)

Earnings

Latest Release
Mar 10, 2025
EPS / Forecast
-0.28 / -0.31
Revenue / Forecast
-- / 1.25M
EPS Revisions
Last 90 days

People Also Watch

1.1200
TNON
0.00%
0.0600
BON
+1.69%
1.8500
NWTG
-1.60%
0.054
PTPI
+28.57%
0.41
AEON
+2.50%

FAQ

What Is the Tenaya Therapeutics (TNYA) Stock Price Today?

The Tenaya Therapeutics stock price today is 0.455

What Stock Exchange Does Tenaya Therapeutics Trade On?

Tenaya Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Tenaya Therapeutics?

The stock symbol for Tenaya Therapeutics is "TNYA."

What Is the Tenaya Therapeutics Market Cap?

As of today, Tenaya Therapeutics market cap is 73.50M.

What is Tenaya Therapeutics Earnings Per Share?

The Tenaya Therapeutics EPS is -1.31.

What Is the Next Tenaya Therapeutics Earnings Date?

Tenaya Therapeutics will release its next earnings report on 06 May 2025.

From a Technical Analysis Perspective, Is TNYA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.